A supervised fasting test measuring glucose, insulin, and C-peptide levels can effectively distinguish between reactive hypoglycemia and insulin-producing tumors in non-diabetic patients, according to a 2026 study of 92 patients. Patients with tumors had blood sugar drop to 39.73 mg/dL versus 55.38 mg/dL in reactive cases, with tumors showing higher insulin levels and faster blood sugar decline during fasting.
When people experience low blood sugar without having diabetes, doctors need to figure out what’s causing it. According to Gram Research analysis, a new study of 92 patients found that a special fasting test can help doctors tell the difference between two main causes: reactive hypoglycemia (where the body overreacts to food) and rare tumors that produce too much insulin. The test involves measuring blood sugar and insulin levels while a person fasts under medical supervision. Researchers discovered that patients with insulin-producing tumors had much lower blood sugar levels and higher insulin levels during the test, and their blood sugar dropped faster. This information helps doctors diagnose the right condition so patients can get the correct treatment.
Key Statistics
A 2026 study of 92 non-diabetic patients found that 87% had reactive hypoglycemia while 13% had insulin-producing tumors, with the supervised fasting test successfully distinguishing between the two conditions using glucose and insulin measurements.
Patients with insulin-producing tumors had blood sugar levels of 39.73 mg/dL during fasting compared to 55.38 mg/dL in reactive hypoglycemia cases, a statistically significant difference that helped doctors identify the correct diagnosis.
In a 2026 analysis of 92 patients, those with insulin-producing tumors developed dangerously low blood sugar after 47 hours of fasting versus 72 hours in reactive hypoglycemia cases, providing an additional diagnostic clue beyond standard blood tests.
A 2026 study of 92 non-diabetic adults found that insulin levels were 6.17 units in patients with tumors compared to 2.57 units in reactive hypoglycemia, and C-peptide was 2.50 versus 0.88 units, both highly significant differences for diagnosis.
The Quick Take
- What they studied: How to tell the difference between two types of low blood sugar that happen in people without diabetes using a supervised fasting test
- Who participated: 92 adults without diabetes who came to a major hospital because they thought they had low blood sugar episodes. The study looked at their medical records from 2020 to 2023
- Key finding: A supervised fasting test combined with blood measurements of glucose, insulin, and C-peptide successfully separated the two types of low blood sugar. Patients with insulin-producing tumors had blood sugar drop to 39.73 mg/dL compared to 55.38 mg/dL in those with reactive hypoglycemia
- What it means for you: If you experience unexplained low blood sugar episodes, this test could help your doctor figure out the exact cause. However, this study was small and looked at past medical records, so larger studies are needed before changing how doctors routinely test for this condition
The Research Details
Researchers reviewed medical records of 92 adults who visited a major hospital between 2020 and 2023 because they had symptoms of low blood sugar. All patients underwent a supervised prolonged fasting test, which means they fasted under medical supervision while doctors measured their blood sugar and hormone levels at regular intervals. The researchers then compared the test results between two groups: those diagnosed with reactive hypoglycemia (where the body produces too much insulin after eating) and those with insulin-producing tumors or other neuroendocrine tumors (rare growths that make too much insulin).
This type of study is called a retrospective observational study, meaning researchers looked backward at information that was already collected rather than following patients forward in time. The doctors used standardized procedures for the fasting test and measured specific blood markers including glucose, insulin, and C-peptide (a protein that shows how much insulin the body is making). They analyzed whether these measurements could reliably distinguish between the two conditions.
The supervised fasting test is important because it creates a controlled situation where doctors can watch what happens to blood sugar levels and measure the body’s response. This helps identify whether low blood sugar is caused by the body overreacting to food or by a tumor making too much insulin. Having a reliable way to tell these apart matters because the treatments are completely different: reactive hypoglycemia is managed with diet changes, while insulin-producing tumors usually require surgery
This study has some strengths and some limitations. The strength is that all patients underwent the same standardized test procedure, which makes comparisons fair. The researchers also measured multiple blood markers rather than relying on just one test. However, the study looked at past medical records rather than following patients forward, which means some information might be missing. The sample size of 92 patients is relatively small, especially since only 12 had tumors. The study was done at one major hospital, so the results might not apply to all populations. The researchers themselves noted that larger, prospective studies are needed to confirm these findings
What the Results Show
The study found that 87% of patients (80 out of 92) had reactive hypoglycemia, while 13% (12 patients) had insulin-producing tumors or other neuroendocrine tumors. When comparing the two groups, patients with tumors had significantly different blood test results. Their blood sugar dropped much lower during fasting, averaging 39.73 mg/dL compared to 55.38 mg/dL in the reactive hypoglycemia group. This difference was highly significant statistically.
Patients with tumors also had much higher insulin levels in their blood (6.17 compared to 2.57 units) and higher C-peptide levels (2.50 compared to 0.88 units). These differences show that patients with tumors were producing excessive amounts of insulin even when their blood sugar was very low, which is the hallmark of this condition. The timing of when blood sugar dropped was also different: in the tumor group, blood sugar fell to dangerously low levels after about 47 hours of fasting, while in the reactive hypoglycemia group it took about 72 hours. This faster drop in the tumor group provided an additional clue for diagnosis.
The study looked at several other blood markers and measurements that doctors sometimes use to evaluate low blood sugar. These included HbA1c (a measure of average blood sugar over time), HOMA-IR (a calculation of insulin resistance), vitamin D levels, and blood cell counts. Interestingly, none of these showed significant differences between the two groups. This finding is important because it suggests that the key diagnostic markers are specifically the glucose, insulin, and C-peptide measurements during the fasting test, rather than other routine blood work
This research builds on existing knowledge about how to diagnose different types of low blood sugar. Previous studies have suggested that the fasting test is useful for this purpose, but this study provides more detailed information about exactly which measurements are most helpful. The finding that C-peptide levels are particularly useful for distinguishing between the two conditions confirms what smaller previous studies have suggested. The study also adds new information about how quickly blood sugar drops in each condition, which hadn’t been emphasized as much in earlier research
Several limitations affect how much we can trust and apply these findings. First, this was a retrospective study looking at past records, so some information may be incomplete or missing. Second, the sample size is small, especially for the tumor group with only 12 patients, which means the results might not be as reliable as studies with more participants. Third, the study was done at one major hospital, so the results might not apply to other hospitals or different populations. Fourth, the study didn’t include any patients with diabetes, so we don’t know if these findings apply to diabetic patients with low blood sugar. Finally, the researchers themselves noted that prospective studies (following patients forward in time) with larger groups are needed to confirm these findings before changing standard medical practice
The Bottom Line
If you experience symptoms of low blood sugar such as shakiness, sweating, confusion, or rapid heartbeat, talk to your doctor about getting evaluated. The supervised fasting test combined with glucose, insulin, and C-peptide measurements appears to be a useful tool for diagnosis, though your doctor will consider your individual situation. This research suggests the test is reliable for distinguishing between reactive hypoglycemia and insulin-producing tumors, but larger studies are still needed. Confidence level: moderate, based on a single study of 92 patients
This research is most relevant for people who experience unexplained low blood sugar episodes and their doctors. It’s particularly important for people whose symptoms don’t fit the typical pattern of reactive hypoglycemia. People with diabetes should not assume these findings apply to them, as this study only included non-diabetic patients. Healthcare providers at major medical centers will likely find this information most useful for diagnostic decision-making
The fasting test itself takes about 72 hours to complete under medical supervision. You should expect results from blood tests within a few days. If a tumor is found, treatment planning would follow. If reactive hypoglycemia is diagnosed, dietary changes can often help within days to weeks. However, individual timelines vary based on the specific diagnosis and treatment plan
Frequently Asked Questions
What is the difference between reactive hypoglycemia and insulinoma?
Reactive hypoglycemia occurs when your body overproduces insulin after eating, causing blood sugar to drop too low. An insulinoma is a rare tumor that continuously makes too much insulin regardless of eating. A fasting test can tell them apart because insulinomas cause blood sugar to drop faster and lower during fasting.
How long does the fasting test for low blood sugar take?
The supervised fasting test typically takes about 72 hours under medical supervision. Doctors monitor your blood sugar and measure insulin levels at regular intervals. Patients with insulin-producing tumors usually develop dangerously low blood sugar within 47 hours, while those with reactive hypoglycemia take longer.
Can I have low blood sugar without diabetes?
Yes, non-diabetic hypoglycemia is a real condition with multiple causes. The most common cause is reactive hypoglycemia, where the body overreacts to food by producing too much insulin. Rare causes include insulin-producing tumors. If you experience unexplained low blood sugar symptoms, see a doctor for proper evaluation.
What blood tests diagnose low blood sugar problems?
The key measurements are glucose (blood sugar), insulin levels, and C-peptide (which shows insulin production). A 2026 study found these three measurements during a supervised fasting test effectively distinguished between reactive hypoglycemia and insulin-producing tumors, with other routine blood work showing no significant differences.
What are symptoms of non-diabetic low blood sugar?
Common symptoms include shakiness, sweating, rapid heartbeat, confusion, anxiety, and fatigue. These typically occur 2 to 3 hours after eating in reactive hypoglycemia or unpredictably in insulinoma cases. If you experience these symptoms regularly, consult your doctor for evaluation and testing.
Want to Apply This Research?
- If you’ve been diagnosed with reactive hypoglycemia, track your blood sugar symptoms (shakiness, sweating, confusion) and the time of day they occur, along with what you ate in the previous 2-3 hours. Record this in a daily log to identify patterns and share with your doctor
- Based on a reactive hypoglycemia diagnosis, users can set reminders to eat balanced meals with protein and healthy fats rather than simple carbohydrates alone. The app could suggest meal timing and composition to help prevent blood sugar crashes
- Create a long-term symptom diary tracking frequency and severity of low blood sugar episodes. Set monthly check-in reminders to review patterns and adjust dietary strategies. If symptoms worsen or change, flag this to discuss with your healthcare provider at your next appointment
This article summarizes research findings and is not a substitute for professional medical advice. If you experience symptoms of low blood sugar such as shakiness, sweating, confusion, or rapid heartbeat, consult a qualified healthcare provider for proper evaluation and diagnosis. The supervised fasting test should only be performed under medical supervision at a healthcare facility. Do not attempt to diagnose yourself or fast without medical guidance. Individual results may vary, and treatment recommendations should be personalized by your healthcare team based on your specific situation.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.